Top Page
Verici Dx Plc
(LSE:VRCI)
Verici Dx Plc (VRCI) vs. iShares MSCI United Kingdom ETF (EWC)
Verici Dx Plc Business Overview & Revenue Model
Verici Dx Plc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.34M | 1.01M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.34M | 1.01M | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.15M | -7.88M | -10.50M | -7.15M | -2.10M |
| Net Income | -5.87M | -8.73M | -11.36M | -8.33M | -7.10M |
Balance Sheet | |||||
| Total Assets | 7.49M | 7.44M | 14.30M | 13.79M | 20.31M |
| Cash, Cash Equivalents and Short-Term Investments | 4.06M | 2.65M | 9.80M | 10.34M | 17.75M |
| Total Debt | 371.00K | 540.00K | 700.00K | 0.00 | 73.55K |
| Total Liabilities | 2.23M | 3.88M | 2.80M | 1.80M | 681.89K |
| Stockholders Equity | 5.26M | 3.56M | 11.51M | 11.98M | 19.62M |
Cash Flow | |||||
| Free Cash Flow | -6.21M | -7.39M | -11.38M | -7.30M | -1.32M |
| Operating Cash Flow | -6.02M | -7.16M | -10.07M | -6.34M | -1.28M |
| Investing Cash Flow | 61.00K | -231.00K | -1.31M | -965.86K | -237.16K |
| Financing Cash Flow | 7.32M | -27.00K | 12.67M | -73.55K | 26.75M |
Verici Dx Plc Technical Analysis
Verici Dx Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £15.11M | ― | ― | ― | 27.60% | 1.35% | |
| ― | £3.89M | ― | -46.41% | ― | -64.18% | 12.05% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | £10.75M | ― | ― | ― | 125.37% | 22.47% | |
| ― | £10.97M | -0.30 | -122.54% | ― | -57.03% | -15.71% | |
| ― | £10.33M | ― | -181.41% | ― | 12.12% | 54.24% | |
| ― | £5.36M | -1.61 | ― | ― | 12.19% | 18.12% |
Verici Dx Plc Corporate Events
Verici Dx plc has announced the appointment of Aubrey Powell as a Non-executive Director, replacing Dr. Erik Lium who has stepped down. Aubrey Powell brings over 30 years of experience in investment banking and corporate finance, with a strong focus on healthcare and life sciences. His expertise is expected to be invaluable as Verici Dx enters a pivotal stage of growth, enhancing its strategic direction and corporate governance.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Verici Dx Plc has reported significant progress in the commercial adoption of its Tutivia™ test, with a 19% increase in ordering clinicians and the onboarding of nine new transplant centers in Q3, now covering 16% of annual transplants in the US. The company has strengthened its commercial team with new hires, anticipating volume growth from Q4, and remains on track to meet market expectations for the year.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Verici Dx Plc has announced significant progress in the adoption of its Tutivia™ test, aimed at detecting acute rejection in transplant patients. The company has onboarded nine new transplant centers in Q3, bringing the total to 30 centers, which account for 16% of annual transplants in the US. Additionally, there has been a 19% increase in ordering clinicians, indicating strong commercial momentum. The company has also expanded its commercial team with new senior sales hires and a Director of Clinical Partnerships, positioning itself to meet market expectations for the full year.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Verici Dx has reported significant commercial progress in the first half of 2025, with the first revenues from their lead product, Tutivia™, a test for acute rejection post-transplant. The company has raised £6.35m to support revenue scale-up, extending their cash runway into H2 2026. Tutivia™ has attained Medicare coverage, facilitating increased adoption across US transplant centers. The company is poised for growth with expanded commercial operations and expects significant acceleration in testing volumes in H2 2025 and beyond.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Verici Dx Plc announced the publication of several abstracts related to its Tutivia™ test ahead of the World Transplant Congress 2025. These abstracts highlight the test’s role in addressing unmet needs in transplant patient care, including managing BK nephropathy and obesity-related complications. The real-world evidence from multiple transplant centers underscores the test’s utility and supports its growing adoption, which is further bolstered by Medicare coverage.
Verici Dx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £0.43 million at an issue price of 0.5 pence per share. This fundraising, combined with previous placements and subscriptions, has generated total gross proceeds of approximately £6.35 million, extending the company’s cash runway into the second half of 2026. The new shares are expected to be admitted to trading on AIM by 30 July 2025, increasing the company’s total ordinary share capital to over 1.5 billion shares. This financial boost is likely to enhance Verici Dx’s operational capabilities and strengthen its position in the clinical diagnostics market.